Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13068627 | 1.00 | NR1H2 (0.55) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL17643760 | 0.89 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL1933168 | 0.89 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL1933164 | 0.89 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL17631559 | 0.89 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL9991418 | 0.89 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL6961673 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL6961671 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL6961675 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL2930155 | 0.87 | NR1H2 (0.65) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885PDE4B 994/4885USP2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.